Table 6. Increases in CK18-Asp396 during different treatment cycles.

Docetaxel (days 5–7)					Vinorelbine (days 5–7)
Cyclea	CK18-Asp396 increase (Ul−1)	Percent increase	(n)	P-valuea	CK18-Asp396 increase (Ul−1)	Percent increase	(n)	P-valuea
1	27 (−5–91)	23.3	43	<0.005	13 (0–51)	11.6	66	0.008
2	29 (−7–86)	22.1	42	<0.013	8 (−10–28)	9.1	65	0.01
3	21 (−2–72)	18.4	35	<0.011	14 (0–40)	17.9	60	0.03
4	36 (4–70)	30.5	33	<0.0004	0 (−18–28)	0	57	0.70
5	36 (1–68)	27.1	31	<0.0004	2 (−10–19)	2.5	51	0.38
6	33 (0–110)	28.4	24	<0.007	0 (−31–53)	0	36	0.64
7	9 (0–48)	7.7	22	<0.022	6 (−22–32)	7.1	29	0.52
8	19 (−7–46)	15.8	19	<0.031	5 (−13–14)	6.8	23	0.54

Of 567 cycles assessed for increases during days 5–7, 181 samples were available from docetaxel cycles 1–8; 294 from vinorelbine cycles 1–8.

^aWilcoxon matched-pairs test.

CK18=Cytokeratin 18.